Teclistamab-Cqyv

Introduction Overview

Generic Name

teclistamab-cqyv

Brand Name

Tecvayli

Dosage Form

subcutaneous injection 30 mg/3 mL (10 mg/mL), 153 mg/1.7 mL (90 mg/mL)

Drug Class

Bispecific T-cell engagers (BiTE)

Pharmacokinetics

Absorption: Tecvayli is administered via subcutaneous injection, which allows for gradual absorption of the monoclonal antibody into systemic circulation. Subcutaneous administration leads to slower absorption compared to intravenous routes, achieving peak plasma concentrations typically within several days post-injection. This absorption profile helps maintain steady therapeutic drug levels and reduces infusion-related reactions.

Distribution: Following absorption, teclistamab-cqyv demonstrates distribution primarily in the vascular and interstitial fluids. As a large protein molecule, its distribution is limited largely to extracellular fluid compartments without extensive penetration into tissues due to molecular size limitations. The volume of distribution is typical of monoclonal antibodies, approximating plasma volume.

Metabolism: Tecvayli, like other monoclonal antibodies, is metabolized through endogenous protein catabolic pathways. It undergoes proteolytic degradation into small peptides and amino acids primarily within the reticuloendothelial system, including macrophages and lysosomes. Unlike small-molecule drugs, it is not metabolized by cytochrome P450 enzymes, minimizing typical hepatic metabolism concerns.

Elimination: The drug is eliminated through nonspecific proteolytic catabolism and recycling via the neonatal Fc receptor (FcRn) pathway, which extends its half-life. Clearance is influenced by target-mediated drug disposition, with higher tumor burden potentially increasing clearance rates. Tecvayli has an elimination half-life that supports weekly or biweekly dosing regimens. Renal or hepatic impairment is not expected to significantly affect elimination given its catabolism is via nonspecific protein degradation pathways.

Dosage Forms

Available Dosage Forms:
Tecvayli is available as single-dose sterile vials intended for subcutaneous injection. The formulations include:
- 30 mg/3 mL vial (10 mg/mL concentration)
- 153 mg/1.7 mL vial (90 mg/mL concentration)

Dosages for Adults and Adolescents:
Tecvayli is indicated for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. The dosing regimen is weight-based (mg/kg) with a step-up dosing schedule to mitigate cytokine release syndrome risk. Initial dosing consists of Step-up Dose 1 (0.06 mg/kg on Day 1), Step-up Dose 2 (0.3 mg/kg on Day 4), followed by the first full treatment dose (1.5 mg/kg on Day 7). Subsequent maintenance dosing is usually weekly at 1.5 mg/kg. Patients achieving and maintaining complete response for at least 6 months may transition to biweekly dosing (1.5 mg/kg every two weeks).

Specific Patient Populations:
Tecvayli is administered under careful supervision with hospitalization recommended for 48 hours post each step-up dose and initial treatment dose to monitor and manage serious adverse events such as cytokine release syndrome and neurotoxicity. Use in pregnancy requires effective contraception and avoidance during breastfeeding due to potential fetal harm. No specific pharmacokinetic adjustments have been defined for renal or hepatic impairment given monoclonal antibody metabolism pathways.

Clinical guidelines emphasize pretreatment with corticosteroids, antihistamines, and antipyretics 1 to 3 hours before step-up doses to reduce adverse effects. Dose modifications or discontinuations may be necessary based on patient tolerability and occurrence of serious toxicities.

Mechanism Of Action

Tecvayli (teclistamab-cqyv) functions as a bispecific T-cell engager (BiTE) antibody designed to simultaneously bind two distinct antigens: B-cell maturation antigen (BCMA) expressed on malignant multiple myeloma plasma cells, and CD3 receptor present on T-cells. This dual binding forms a cytolytic synapse that activates T-cells directly adjacent to the myeloma cells, bypassing the need for conventional antigen presentation.

Upon binding BCMA on tumor cells and CD3 on T-cells, Tecvayli promotes crosslinking, leading to T-cell activation and proliferation. Activated T-cells subsequently release perforin and granzymes, inducing apoptosis of the myeloma cells. Furthermore, T-cell cytokine production is increased, enhancing the immune-mediated tumor cell killing.

This mechanism enhances immune surveillance by recruiting endogenous T-cells to recognize and lyse multiple myeloma cells expressing BCMA, which are typically resistant to immune attack. Tecvayli’s innovative approach leverages the patient's own immune system to execute targeted cytotoxicity, reducing reliance on conventional chemotherapeutics.

Clinical trials have demonstrated that this mechanism results in significant anti-myeloma activity in heavily pretreated patients. Compared with other immunotherapeutics like CAR T-cell therapies that require complex ex vivo modification, Tecvayli offers an off-the-shelf, subcutaneously administered therapy harnessing direct T-cell redirection. The dual specificity enhances precision and reduces off-target effects compared to monospecific antibodies.

Pharmacological Actions

Bispecific binding to BCMA on myeloma cells and CD3 on T-cells to form a cytolytic synapse
Activation and proliferation of endogenous cytotoxic T-cells
Induction of tumor cell apoptosis through perforin and granzyme-mediated cytotoxicity
Modulation of immune environment to enhance anti-tumor immune responses
Targeted immunotherapy specifically for relapsed or refractory multiple myeloma
Reduction of tumor burden by immune-mediated killing
Minimal off-target immune activation due to dual antigen specificity
Immunomodulatory effects enhancing T-cell effector function and cytokine secretion
Step-up dosing decreases risk of severe cytokine release syndrome
Subcutaneous administration allowing gradual systemic exposure and improved tolerability
Potential to overcome resistance mechanisms inherent in heavily pretreated multiple myeloma
Shortens T-cell exhaustion status, maintaining sustained immune activity
Synergistic use with corticosteroids to mitigate immune-related adverse events
Engages innate and adaptive immune responses via T-cell redirection

Therapeutic Or Clinical Uses

Treatment of adult patients with relapsed or refractory multiple myeloma
Indicated for patients who have received at least four prior lines of therapy including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies
Utilized to slow disease progression in refractory multiple myeloma
Used in patients unable to tolerate or refractory to conventional chemotherapy
Improves quality of life by controlling disease-related symptoms
Option for heavily pretreated multiple myeloma patients with limited alternatives
Maintenance therapy post best response to decrease relapse risk
Adjunct to other myeloma therapies in clinical trials and combination regimens
Management of measurable residual disease through immune-mediated clearance
Potential role in earlier lines of therapy under clinical evaluation
Treatment in patients refractory to CAR T-cell therapy
Provides a non-cellular immunotherapeutic alternative to CAR T-cell approaches
Can be administered in outpatient settings after initial monitored dosing
Bridges patients to stem cell transplantation or other therapeutic modalities
Treats disease manifestations related to BCMA-expressing malignant plasma cells

Side Or Adverse Effects

Injection site reactions including pain, bruising, swelling, and irritation
Headache and neurological symptoms such as tremors or confusion
Cytokine release syndrome characterized by fever, chills, hypotension, and respiratory symptoms
Nausea, diarrhea, and gastrointestinal discomfort
Fatigue, weakness, and generalized malaise
Musculoskeletal pain including joint and muscle pain
Respiratory symptoms like cough, chest pain, and shortness of breath
Infections due to immunosuppression or neutropenia, including fever and sore throat
Neurological toxicities such as numbness, tingling, double vision, and muscle spasms
Potential liver dysfunction manifesting as jaundice, elevated liver enzymes, and abdominal pain
Risk of allergic reactions including anaphylaxis and angioedema
Bruising, swelling, redness, or bleeding at injection sites
Possible hematologic abnormalities including cytopenias
Delayed wound healing or increased susceptibility to infection around injection areas
Rare reports of serious adverse events requiring hospitalization or treatment discontinuation

Precautions

Hospitalization recommended for 48 hours post initial step-up dosing to monitor for cytokine release syndrome and neurologic events
Premedication with corticosteroids, antihistamines, and antipyretics required prior to step-up doses to reduce adverse event risk
Avoid driving or operating hazardous machinery for 48 hours after dosing or while experiencing neurologic symptoms
Monitor closely for signs of infection during treatment due to immunosuppressive effects
Regular hematologic and liver function assessments during therapy
Pregnancy prevention required during treatment and for at least 5 months after last dose due to fetal risk
Discontinue breastfeeding during treatment and for at least 5 months post-therapy
Dose modifications, temporary interruption, or discontinuation may be necessary for severe toxicities
Educate patients on symptoms of cytokine release syndrome and neurologic toxicity for prompt reporting
Use caution in patients with preexisting neurological disorders or impaired immune systems
Screen and treat infections prior to initiating therapy
Assess baseline organ function to identify risk of treatment complications
Maintain hydration and supportive care during treatment to mitigate adverse effects
Avoid live vaccines during and after treatment due to immune suppression
Ensure comprehensive patient education on drug administration and monitoring protocols

Warnings

High risk of Cytokine Release Syndrome (CRS) manifested by fever, hypotension, hypoxia, and organ dysfunction; immediate medical attention required
Neurologic toxicities including encephalopathy, seizures, confusion, tremors, and motor deficits may occur
Serious infections including bacterial, viral, and fungal infections due to immunosuppression
Allergic reactions including anaphylaxis can be life-threatening
Patients must remain hospitalized for observation during initial dosing to promptly manage adverse events
Delayed or permanent discontinuation of therapy may be necessary if severe toxicities develop
Contraindicated use during pregnancy due to potential teratogenicity and fetal harm
Use with caution in patients with prior neurological conditions or baseline immunodeficiency
Risk of hepatotoxicity with signs including jaundice, elevated liver enzymes, and abdominal pain
Monitor blood counts routinely to detect early hematologic toxicity
Potential impaired ability to mount effective immune responses upon exposure to infections
Risk of injection site reactions requiring medical management
Discontinue breastfeeding during therapy and for a minimum of 5 months thereafter
Patients should be enrolled in the Tecvayli REMS program ensuring appropriate monitoring and risk mitigation
Use carefully in elderly patients or those with significant comorbid conditions due to limited safety data

Contraindication

Hypersensitivity or allergy to teclistamab-cqyv or any component of the formulation
Active, uncontrolled infections at the time of treatment initiation
Pregnancy due to teratogenic risk and potential fetal harm
Breastfeeding due to potential excretion in human milk and unknown effects on infant
Concurrent participation in other investigational drug studies without prior consultation
Patients with severe baseline neurological disorders that could be exacerbated by therapy
Known severe immunodeficiency states without adequate control
Uncontrolled or severe hepatic impairment given potential for increased toxicity
History of severe cytokine release syndrome from previous immunotherapies
Conditions where hospitalization for monitoring is not feasible, due to required post-dose observation
Use with caution or contraindicated in patients unable to adhere to REMS program monitoring requirements
Previous severe hypersensitivity reactions to monoclonal antibodies without desensitization feasibility
Known hypersensitivity to excipients such as polysorbate 20 or sucrose present in the formulation
Uncontrolled cardiovascular disease that could complicate adverse event management
Patients with active central nervous system infections or symptoms

Drug Interactions

Potential additive immunosuppressive effects with concomitant corticosteroids and immunomodulatory agents
No significant cytochrome P450 mediated interactions expected due to monoclonal antibody metabolism
Concurrent use with other biologic therapies may increase risk of infections and immunotoxicity
Interactions with live vaccines not recommended; vaccination efficacy may be reduced
Co-administration with agents causing QT prolongation requires monitoring due to risk of cardiac events
Concomitant drugs causing myelosuppression may potentiate hematologic toxicity
Potential interference with other therapeutic antibodies targeting immune cells
Antihistamines and antipyretics used as premedication help mitigate cytokine release syndrome risk
No known interactions with common chemotherapy agents, but careful clinical monitoring advised
Limited interaction data with herbal or dietary supplements; caution recommended
Immunosuppressants may reduce the efficacy of Tecvayli due to dampened T-cell activity
Avoid strong CYP inducers/inhibitors is rarely clinically relevant but monitor for unforeseen effects
Close monitoring when combining with antifungal or antiviral prophylactics due to immunosuppression
Potential pharmacodynamic interactions that may increase neurotoxicity with concurrent neurotoxic drugs
Concomitant use with anticoagulants requires vigilance for bleeding complications due to thrombocytopenia risk

Preparations Of The Drug

Tecvayli supplied as sterile, preservative-free single-dose vials
Two vial strengths: 30 mg/3 mL (10 mg/mL) and 153 mg/1.7 mL (90 mg/mL)
Formulated with inactive ingredients including edetate disodium, glacial acetic acid, polysorbate 20, sodium acetate, sucrose, and Water for Injection
Requires refrigeration at 2°C to 8°C (36°F to 46°F) and protection from light in original carton
Do not freeze or shake; gentle handling necessary to maintain stability
Administered by trained healthcare professionals via subcutaneous injection in abdominal area or thigh
Discard any unused portion after single-dose vial opening
Requires reconstitution or dilution not necessary; ready-to-use liquid formulation
Accompanied by patient wallet card outlining serious adverse event information
Provided with package insert detailing dosage, administration, safety, and storage instructions
Included in a Risk Evaluation and Mitigation Strategy (REMS) program due to serious toxicities
Vials labeled with National Drug Codes (NDC 57894-449-01 for 30 mg and 57894-450-01 for 153 mg)
Manufactured by Janssen Biotech, Inc. under strict quality control procedures
Strict adherence to cold chain logistics required to ensure product efficacy and safety
Disposal per institutional policy for cytotoxic and biological agents